1. Home
  2. SKE vs CELC Comparison

SKE vs CELC Comparison

Compare SKE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skeena Resources Limited

SKE

Skeena Resources Limited

HOLD

Current Price

$35.06

Market Cap

4.1B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$92.87

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKE
CELC
Founded
1979
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.2B
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
SKE
CELC
Price
$35.06
$92.87
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$112.56
AVG Volume (30 Days)
511.9K
862.5K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$37,573.35
$720.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.42
$44.42
52 Week High
$38.77
$151.02

Technical Indicators

Market Signals
Indicator
SKE
CELC
Relative Strength Index (RSI) 66.14 50.94
Support Level $24.88 $82.59
Resistance Level $34.73 $95.59
Average True Range (ATR) 1.17 4.35
MACD 0.26 0.65
Stochastic Oscillator 80.86 75.97

Price Performance

Historical Comparison
SKE
CELC

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: